Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
98 hedge funds and large institutions have $119M invested in Adverum Biotechnologies in 2021 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 26 increasing their positions, 39 reducing their positions, and 26 closing their positions.
399% more call options, than puts
Call options by funds: $5.58M | Put options by funds: $1.12M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.42% less ownership
Funds ownership: 7.13% → 6.72% (-0.42%)
11% less funds holding
Funds holding: 110 → 98 (-12)
23% less capital invested
Capital invested by funds: $155M → $119M (-$35.9M)
33% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 39
46% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$2.1M |
| 2 |
CAC
Cowen and Company
New York
|
+$1.95M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.76M |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.05M |
| 5 |
QOP
Quinn Opportunity Partners
Charlottesville,
Virginia
|
+$510K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$2.47M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$2.06M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2.02M |
| 4 |
Morgan Stanley
New York
|
-$1.93M |
| 5 |
Millennium Management
New York
|
-$1.5M |
ADVM Hedge Fund Activity: Q4 2021 in Review
98 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q4 2021, worth a combined $119M — down 23% from $155M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of ADVM and 14 opened new positions — a net loss of 12 holders — while 39 trimmed existing stakes and 26 added.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $2.1M. The largest seller was K2 Principal Fund, cutting an estimated $2.47M.
- 98 institutional investors held Adverum Biotechnologies (ADVM) as of Q4 2021, down from 110 in Q3 2021.
- Funds reported $119M of Adverum Biotechnologies stock for Q4 2021, down 23% quarter-over-quarter.
- 14 funds opened new Adverum Biotechnologies positions in Q4 2021 and 26 closed out, a net change of -12 holders.
- The largest Adverum Biotechnologies buyer in Q4 2021 was EcoR1 Capital, an estimated $2.1M added.
- The largest Adverum Biotechnologies seller in Q4 2021 was K2 Principal Fund, an estimated $2.47M sold.
Based on aggregated 13F filings for Q4 2021.